PMDA
- Application: Augtyro
- Local brand name: Augtyro
- Status: approved
🇯🇵 Augtyro in Japan
Augtyro (REPOTRECTINIB) regulatory status in Japan.
Marketing authorisation
Augtyro in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Japan
Frequently asked questions
Is Augtyro approved in Japan?
Yes. PMDA has authorised it.
Who is the marketing authorisation holder for Augtyro in Japan?
Bristol is the originator. The local marketing authorisation holder may differ — check the official source linked above.